To be honest, that does not seem to be inordinately long considering they are squirting a novel synthetic polymer up somebody's arm and hoping it does not do them any unexpected harm. If the company has discussed the trial process with the appropriate medical committees and that is how they have been guided to stage things I think that is probably reasonable. Thus far we have learned that they can do that to a very large extent. Then the PK indications are that it goes rapidly into the bladder, where, lo and behold, it would appear that it has a great potential to treat UTIs. Hence the addition of new UTI specific evaluations, starting with ex vivo trials to at least prove it works in urine. It strikes me that if anything there has been a lot of wise prudence exercised in establishing all the behaviour of the drug in vivo before giving to people with infections that are by definition very serious conditions. I would personally rather there had been prudence than adverse reactions or major failures or unexpected side issues. Killing patients has such a bad ring to it.
However if anyone here who seriously wishes to jump ahead of all this unnecessary prudence and time wasting, maybe you would like to volunteer to get given dose of e.coli for a day or two and then have R327 squirted up your arm. Sounds like an easy solution to all the slow progress. And you would be doing the rest of the shareholders a service too. Any volunteers still out there?
RCE Price at posting:
46.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)